CLASS II Drug recall · Reported 6 Feb 2019 · FDA Enforcement Report

Irbesartan Tablets 300 mg recalled by Prinston Pharmaceutical

Prinston Pharmaceutical is recalling Irbesartan Tablets 300 mg, distributed nationwide in the US. The recall was initiated on 18 Jan 2019 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codes331B18009
NDC43547-374, 43547-375, 43547-376
Quantity recalled19800 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0409-2019
FDA event ID
81910
Recalling firm
Prinston Pharmaceutical, Somerset, NJ
Manufacturer
Solco Healthcare U.S., LLC
Classification
Class II
Status
Completed
Recall initiated
18 Jan 2019
FDA classified
27 Jan 2019
Reported
6 Feb 2019
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity

Timeline

18 Jan 2019Recall initiated by company
27 Jan 2019Classified by FDA+9 days
6 Feb 2019Published in enforcement report+10 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Irbesartan Tablets 300 mg 90 count Rx only Manufactured by: Zhejiang Huahai Pharmaceutical Co., Xunqiao, Linhai, Zhejiang 317024 China Distributed by: Solco Healthcare US, LLC Cranbury, NJ 08512 NDC 43547-376-09

Where it was distributed

Nationwide

Nationwide

Questions about this recall

Is Irbesartan Tablets 300 mg recalled?

Yes. Prinston Pharmaceutical recalled Irbesartan Tablets 300 mg on 18 Jan 2019. The recall is Class II and its status is Completed. Recall number D-0409-2019.

Why was it recalled?

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Which lots are affected?

331B18009

Where was it sold?

Nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Prinston Pharmaceutical

All 16

Other Irbesartan recalls

All 16